Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now full pipeline small index

Uterine Fibroids: full-pipeline trial registry

2 of 11 indexed Uterine Fibroids trials are currently recruiting.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 2 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Uterine Fibroids: 11 US clinical trials tracked, 2 recruiting.

Uterine Fibroids is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is University of California, San Francisco, running 3 of these trials.

Enrollment posture brief

Registry condition uterine-fibroids

OPEN 2 | RECR 18% | LATE 2 | EARLY 3 | RANK #1577 | SPON 3

Nearest open-share peer: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (18% recruiting · 22 trials)

Acute Pancreatitis81.8%Acute Stroke45.5%Acquired Brain Injury36.4%Uterine Fibroids (this)18%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Uterine Fibroids

Uterine Fibroids lists 2 open slots (18% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Uterine Fibroids on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Uterine Fibroids is recruiting below its size-band peers.

    2 of 11 indexed trials (18.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Uterine Fibroids research.

    University of California, San Francisco accounts for 3 of 11 trials (27.3%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most Uterine Fibroids trials plan to enrol fewer than 100 people.

    Median target enrolment is 42 among the 11 trials that report a genuine target (sentinel values excluded). 8 of those (72.7%) plan for fewer than 100 participants.

  4. Uterine Fibroids research is mostly interventional.

    9 interventional and 2 observational studies make up this index (81.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22Phase 32

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 3 1,000 participants

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Sumitomo Pharma Switzerland

NCT05862272

RECRUITING NA 42 participants

An Open-Label Study to Evaluate the Effect of Elix Cycle Balance & Elix Daily Harmony on Fibroid-related Symptoms

Zenchi

NCT07078682

ACTIVE NOT RECRUITING 578 participants

Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry

University of California, San Francisco

NCT02100904

ACTIVE NOT RECRUITING Early Phase 1 28 participants

Effect of Addition of Steroids on Duration of Analgesia

University of California, Los Angeles

NCT04126824

COMPLETED Phase 3 526 participants

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

ObsEva

NCT03070899

COMPLETED NA 78 participants

Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy

University of South Florida

NCT02472184

COMPLETED Phase 2 65 participants

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

Repros Therapeutics

NCT00958334

COMPLETED Phase 2 40 participants

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

Repros Therapeutics

NCT01451424

COMPLETED 38 participants

Biologic Predictors of Leiomyoma Treatment Outcomes

Elizabeth A. Stewart

NCT01936493

COMPLETED NA 26 participants

Uterine Leiomyoma Treatment With Radiofrequency Ablation

University of California, San Francisco

NCT01840124

COMPLETED NA 20 participants

Magnetic Resonance Guided Focused Ultrasound for Uterine Fibroids

University of California, San Francisco

NCT01377519

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 3 2

Named interventions

Most-linked intervention names on Uterine Fibroids records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Radiofrequency ablation of fibroids Procedure
2 trials
Proellex Drug
1 trials
Placebo MR Guided Focused Ultrasound Procedure
1 trials
MR Guided Focused Ultrasound Procedure
1 trials
Add-back Drug
1 trials
Placebo to match Add-back Drug
1 trials
Placebo to match OBE2109 Drug
1 trials
OBE2109 Drug
1 trials

US sites by state

Facility locations filed on Uterine Fibroids trials. A trial with sites in several states counts in each.

California 7 trials
Texas 3 trials
Florida 3 trials
Colorado 3 trials
Arizona 3 trials
Nevada 2 trials
North Carolina 2 trials
Alabama 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Uterine Fibroids page

11 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Uterine Fibroids condition card totals 11 registered trials; most-linked intervention Radiofrequency ablation of fibroids; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.